Status:
COMPLETED
Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Acute Myocardial Infarction
Left Ventricular Thrombosis
Eligibility:
All Genders
18-100 years
Phase:
PHASE3
Brief Summary
Patients with acute ST-segment elevation myocardial infarction (STEMI) have an elevated risk of stroke, most of which are cardio-embolic in origin as a result of left ventricular (LV) thrombus formati...
Detailed Description
Background and Study Rationale: Patients with acute ST-segment elevation myocardial infarction (STEMI) have an elevated risk of stroke, most of which are cardio-embolic in origin as a result of left ...
Eligibility Criteria
Inclusion
- Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography
- Acute MI in last 3 months prior to enrollment
Exclusion
- Patients with contraindications for chronic anti coagulation
- Patients with severe renal failure (CrCl\< 15 ml/min)
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03232398
Start Date
January 1 2018
End Date
May 31 2021
Last Update
August 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel